{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:45:07Z","timestamp":1789227907836,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Linezolid is an oxazolidinone antibiotic widely used to treat infections caused by resistant Gram-positive bacteria. It has long been regarded as a drug that does not require therapeutic drug monitoring, owing to its limited pharmacokinetic variability. However, recent clinical observations suggest that delayed linezolid elimination is associated with hematological toxicity and thrombocytopenia, particularly in older adults and individuals with reduced renal function. As Japan has a rapidly aging population, understanding real-world linezolid prescription patterns is important for contextualizing potential safety concerns related to its use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study analyzed Japanese national linezolid prescription trends using publicly available data from the National Database of Health Insurance Claims. The annual prescription counts of oral and parenteral linezolid formulations were descriptively examined in inpatient and outpatient settings, along with age- and sex-specific distributions. To provide comparative context, inpatient trends in parenteral use of major anti- methicillin-resistant\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      (MRSA) agents were also assessed using the same data source.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Inpatient use declined steadily from 2014 to 2023. Outpatient use remained extremely limited for most of the study period; however, oral outpatient prescriptions became observable from 2022 onward, though the absolute magnitude remained small. Given that outpatient care generally involves less intensive clinical monitoring, even limited outpatient use warrants careful interpretation. Age-stratified analysis revealed that prescriptions were concentrated among older adults, with the highest use observed in individuals aged 85\u201389\u2009years. These patients are more likely to have reduced renal function, which can further increase drug exposure and the risk of toxicity. Stratified analyses further demonstrated that outpatient oral use was almost exclusively observed among older adults. In the comparative inpatient analysis of parenteral anti-MRSA agents, trends differed by agent, indicating that the decline in linezolid use did not simply reflect uniform changes in inpatient anti-MRSA antibiotic utilization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These national prescribing patterns indicate that linezolid continues to be used predominantly among older adults. Although causal relationships cannot be inferred from this descriptive analysis, the findings highlight clinical contexts in which careful monitoring of linezolid therapy may be particularly important. Further evaluation is warranted to determine whether monitoring strategies, including the potential role of therapeutic drug monitoring, could contribute to safer use of linezolid in high-risk patient populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-026-00552-8","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T08:54:23Z","timestamp":1770800063000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Trends in Linezolid Prescription in Japan based on National database open Data: implications for the need for therapeutic drug monitoring"],"prefix":"10.1186","volume":"12","author":[{"given":"Yuichi","family":"Muraki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Ohmagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"552_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ijantimicag.2003.11.003","volume":"23","author":"B Bozdogan","year":"2004","unstructured":"Bozdogan B, Appelbaum PC. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents. 2004;23:113\u201319. https:\/\/doi.org\/10.1016\/j.ijantimicag.2003.11.003.","journal-title":"Int J Antimicrob Agents"},{"key":"552_CR2","doi-asserted-by":"publisher","unstructured":"MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother. 2003;51 Suppl,(2):ii17\u201325. https:\/\/doi.org\/10.1093\/jac\/dkg248.","DOI":"10.1093\/jac\/dkg248"},{"key":"552_CR3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","volume":"44","author":"K Matsumoto","year":"2014","unstructured":"Matsumoto K, Shigemi A, Takeshita A, Watanabe E, Yokoyama Y, Ikawa K, et al. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients. Int J Antimicrob Agents. 2014;44:242\u201347. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.05.010.","journal-title":"Int J Antimicrob Agents"},{"key":"552_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s40360-022-00628-9","volume":"23","author":"X Liu","year":"2022","unstructured":"Liu X, Aoki M, Osa S, Ito C, Saiki R, Nagai T, et al. Safety of linezolid in patients with decreased renal function and trough monitoring: a systematic review and meta-analysis. BMC Pharmacol Toxicol. 2022;23:89. https:\/\/doi.org\/10.1186\/s40360-022-00628-9.","journal-title":"BMC Pharmacol Toxicol"},{"key":"552_CR5","doi-asserted-by":"publisher","unstructured":"Crass RL, Cojutti PG, Pai MP, Pea F. Reappraisal of linezolid dosing in renal impairment to improve safety. Antimicrob Agents Chemother. 2019;63:e00605\u201319. https:\/\/doi.org\/10.1128\/AAC.00605-19.","DOI":"10.1128\/AAC.00605-19"},{"key":"552_CR6","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s10157-024-02570-y","volume":"29","author":"A Kobayashi","year":"2025","unstructured":"Kobayashi A, Hirano K, Okuda T, Ikenoue T, Yokoo T, Fukuma S. Estimating the prevalence of chronic kidney disease in the older population using health screening data in Japan. Clin Exp Nephrol. 2025;29:276\u201382. https:\/\/doi.org\/10.1007\/s10157-024-02570-y.","journal-title":"Clin Exp Nephrol"},{"key":"552_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40780-023-00317-7","volume":"9","author":"K Mizuno","year":"2023","unstructured":"Mizuno K, Inose R, Yoshimura Y, Muraki Y. Relationship between antihypertensive drug use and number of people with high blood pressure in FY 2018: a descriptive epidemiological study based on the National Database of Health Insurance Claims and specific Health Checkups of Japan open data. J Pharm Health Care Sci. 2023;9:47. https:\/\/doi.org\/10.1186\/s40780-023-00317-7.","journal-title":"J Pharm Health Care Sci"},{"key":"552_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.7883\/yoken.JJID.2021.450","volume":"75","author":"T Nakanishi","year":"2022","unstructured":"Nakanishi T, Inose R, Kusama Y, Ishikane M, Kajihara T, Yahara K, et al. The use of topical antibiotics based on the national database of health insurance claims and specific health checkups of Japan (NDB) open data in 2017. Jpn J Infect Dis. 2022;75:177\u201382. https:\/\/doi.org\/10.7883\/yoken.JJID.2021.450.","journal-title":"Jpn J Infect Dis"},{"key":"552_CR9","unstructured":"Ministry of Health. Labour and Welfare, Open data NDB. https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000177182.html. Internet]; 2025. Accessed 2025 Dec 5."},{"key":"552_CR10","unstructured":"Ministry of internal affairs and communications statistics bureau; 2025. . Population Estimates [Internet]. https:\/\/www.stat.go.jp\/data\/jinsui\/2023np\/index.html. Accessed 2025 Dec 5."},{"key":"552_CR11","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2146\/ajhp130482","volume":"71","author":"JJ Kisgen","year":"2014","unstructured":"Kisgen JJ, Mansour H, Unger NR, Childs LM. Tedizolid: a new oxazolidinone antimicrobial. Am J Health Syst Pharm. 2014;71:621\u201333. https:\/\/doi.org\/10.2146\/ajhp130482.","journal-title":"Am J Health Syst Pharm"},{"key":"552_CR12","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/S1473-3099(17)30325-0","volume":"17","author":"D Baur","year":"2017","unstructured":"Baur D, Gladstone BP, Burkert F, Carrara E, Foschi F, D\u00f6bele S, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17:990\u20131001. https:\/\/doi.org\/10.1016\/S1473-3099(17)30325-0.","journal-title":"Lancet Infect Dis"},{"key":"552_CR13","unstructured":"Ministry of Health. Labour and Welfare, Japan nosocomial infections surveillance JANIS Open report. https:\/\/janis.mhlw.go.jp\/english\/report\/open_report\/2024\/3\/1\/ken_Open_Report_Eng_202400_clsi2012.pdf. Internet]; 2025. Accessed 2025 Dec 5."},{"key":"552_CR14","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jiac.2019.10.017","volume":"26","author":"S Tsuzuki","year":"2020","unstructured":"Tsuzuki S, Matsunaga N, Yahara K, Gu Y, Hayakawa K, Hirabayashi A, et al. National trend of blood-stream infection attributable deaths caused by Staphylococcus aureus and Escherichia coli in Japan. J Infect Chemother. 2020;26:367\u201371. https:\/\/doi.org\/10.1016\/j.jiac.2019.10.017.","journal-title":"J Infect Chemother"},{"key":"552_CR15","doi-asserted-by":"publisher","unstructured":"Yamaguchi S, Okada A, Sunaga S, Ikeda Kurakawa K, Yamauchi T, Nangaku M, et al. Impact of COVID-19 pandemic on healthcare service use for non-COVID-19 patients in Japan: retrospective cohort study. BMJ Open. 2022;12:e060390. https:\/\/doi.org\/10.1136\/bmjopen-2021-060390.","DOI":"10.1136\/bmjopen-2021-060390"},{"key":"552_CR16","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1248\/bpb.b20-00605","volume":"43","author":"R Goto","year":"2020","unstructured":"Goto R, Inose R, Kusama Y, Kawabe A, Ishii S, Ebisui A, et al. Trends of the use of anti-methicillin-resistant Staphylococcus aureus agents in Japan based on sales data from 2006 to 2015. Biol Pharm Bull. 2020;43:1906\u201310. https:\/\/doi.org\/10.1248\/bpb.b20-00605.","journal-title":"Biol Pharm Bull"},{"key":"552_CR17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1248\/bpb.b24-00784","volume":"48","author":"R Goto","year":"2025","unstructured":"Goto R, Inose R, Koizumi R, Sawada K, Ishikane M, Ohmagari N, et al. Evaluation of the influence of the National action plan on antimicrobial resistance and the COVID-19 pandemic on the consumption of broad-spectrum antimicrobial and anti-methicillin-resistant Staphylococcus aureus agents. Biol Pharm Bull. 2025;48:415\u201321. https:\/\/doi.org\/10.1248\/bpb.b24-00784.","journal-title":"Biol Pharm Bull"},{"key":"552_CR18","doi-asserted-by":"publisher","unstructured":"Guppy M, Thomas ET, Glasziou P, Clark J, Jones M, O\u2019Hara DV, et al. Rate of decline in kidney function with age: a systematic review. BMJ Open. 2024;14:e089783. https:\/\/doi.org\/10.1136\/bmjopen-2024-089783.","DOI":"10.1136\/bmjopen-2024-089783"},{"key":"552_CR19","doi-asserted-by":"publisher","unstructured":"Norris AH, Shrestha NK, Allison GM, Keller SC, Bhavan KP, Zurlo JJ, et al. Infectious diseases Society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapy. 2019, . Clin Infect Dis. 2018;68:e1\u201335. https:\/\/doi.org\/10.1093\/cid\/ciy745.","DOI":"10.1093\/cid\/ciy745"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-026-00552-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00552-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00552-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:05:07Z","timestamp":1781633107000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40780-026-00552-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["552"],"URL":"https:\/\/doi.org\/10.1186\/s40780-026-00552-8","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"YM received grants from Pfizer Japan Inc., Kowa Company Ltd., the Japan Pharmaceutical Association, the Japan Society for the Promotion of Science. YM is a board member of the Japanese Society of Pharmaceutical Health Care and Sciences and the Japanese Society for Infection Prevention and Control and is a committee member of the AMR Clinical Reference Center. However, this study was not directly related to that funding. NO declares no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}